鶹ý

Speech Predicts Alzheimer's; Afib and Dementia in Women; Who Gets Lecanemab?

— News and commentary from the world of neurology and neuroscience

MedpageToday
Neuro Break over a computer rendering of neurons.

Automated detection of may predict disease progression, a longitudinal analysis suggested. (Alzheimer's & Dementia)

More blood pressure-lowering medications than those included in treatment guidelines frequency. (Cephalalgia)

Olfactory dysfunction of subsequent depressive symptoms. (Journals of Gerontology: Series A)

Cholinesterase inhibitors were tied to small improvements on in Alzheimer's disease and Parkinson's disease, a meta-analysis suggested. (JAMA Neurology)

Atrial fibrillation was associated with to mild cognitive impairment and dementia in women. (Alzheimer's & Dementia)

The FDA approved argenx's (Vyvgart Hytrulo) for generalized myasthenia gravis patients who are anti-acetylcholine receptor antibody positive, Halozyme Therapeutics said.

CMS of its plan to cover new Alzheimer's drugs.

Experts discussed (Leqembi) if the anti-amyloid Alzheimer's drug wins full FDA approval next week -- and who might not. (NPR)

The Semont-plus maneuver was superior to the Epley maneuver in terms of the number of days until recovery in posterior canal . (JAMA Neurology)

New multiple sclerosis (MS) lesions that evolved into may be identified early. (Annals of Neurology)

People with progressive MS had a than those with relapsing remitting MS (RRMS), and anti-CD20 therapies in RRMS were associated with severe COVID-19. (JAMA Network Open)

A multilevel analysis of the gut-brain axis showed and specific microbial profiles. (Nature Neuroscience)

  • Judy George covers neurology and neuroscience news for 鶹ý, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.